Login / Signup

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

Ricardo D ParrondoBetsy R LaPlantJamie ElliottAndre FernandezCaitlin J FlottDiedre ArringtonDustin ChapinJade BrownSaurav DasVivek RoyAsher A Chanan-KhanSikandar Ailawadhi
Published in: Blood cancer journal (2024)
Keyphrases
  • multiple myeloma
  • high dose
  • low dose
  • open label
  • placebo controlled
  • clinical trial
  • randomized controlled trial